Trial reportOncotarget2016
Urinary mRNA biomarker panel for the detection of urothelial carcinoma.
Trial report in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- Urinary transcript quantitation of CK20 and IGF2 for the non-invasive bladder cancer detection.Journal of cancer research and clinical oncology · 2017Trial
- Application of PLK1 and HOXA13 Gene Expression Levels in Urine in the Diagnosis of Non-muscle Invasive Bladder Cancer.Biochemical genetics · 2025Article
- Exploring a Desirable Quadr-mRNAs Panel for Non-invasive and Ultrasensitive Bladder Cancer Diagnosis:Current medicinal chemistry · 2025Article
- Unveiling the Dichotomy of Urinary Proteins: Diagnostic Insights into Breast and Prostate Cancer and Their Roles.Proteomes · 2023Review
- Urine as a Source of Liquid Biopsy for Cancer.Cancers · 2021Review
- Urinary microRNA and mRNA in Tumors.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Urinary MicroRNAs as Potential Markers for Non-Invasive Diagnosis of Bladder Cancer.International journal of molecular sciences · 2020Article
- Urine biopsy technologies: Cancer and beyond.Theranostics · 2020Review
- MicroRNA Biomarkers for Infectious Diseases: From Basic Research to Biosensing.Frontiers in microbiology · 2020Review
- CD24 regulates cancer stem cell (CSC)-like traits and a panel of CSC-related molecules serves as a non-invasive urinary biomarker for the detection of bladder cancer.British journal of cancer · 2018Article
- Analysis of extracellular mRNA in human urine reveals splice variant biomarkers of muscular dystrophies.Nature communications · 2018Article
- Liquid Biopsy Biomarkers in Bladder Cancer: A Current Need for Patient Diagnosis and Monitoring.International journal of molecular sciences · 2018Review
- Validation of Urine-based Gene Classifiers for Detecting Bladder Cancer in a Chinese Study.Journal of Cancer · 2018Article
- Spectrophotometric photodynamic detection involving extracorporeal treatment with hexaminolevulinate for bladder cancer cells in voided urine.Journal of cancer research and clinical oncology · 2017Article
- Deep Sequencing of Urinary RNAs for Bladder Cancer Molecular Diagnostics.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- Circulating microRNAs as novel biomarkers of ALK-positive nonsmall cell lung cancer and predictors of response to crizotinib therapy.Oncotarget · 2017Article
- Article
- Liquid biopsies for surveillance and monitoring treatment response of bladder cancer.Annals of translational medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
The early detection of bladder cancer is important as the disease has a high rate of recurrence and progression. The development of accurate, non-invasive urinary assays would greatly facilitate detection. In previous studies, we have reported the discovery and initial validation of mRNA biomarkers that may be applicable in this context. In this study, we evaluated the diagnostic performance of proposed molecular signatures in an independent cohort.Forty-four mRNA transcripts were monitored blindly in urine samples obtained from a cohort of 196 subjects with known bladder disease status (89 with active BCa) using quantitative real-time PCR (RT-PCR). Statistical analyses defined associations of individual biomarkers with clinical data and the performance of predictive multivariate models was assessed using ROC curves. The majority of the candidate mRNA targets were confirmed as being associated with the presence of BCa over other clinical variables. Multivariate models identified an optimal 18-gene diagnostic signature that predicted the presence of BCa with a sensitivity of 85% and a specificity of 88% (AUC 0.935). Analysis of mRNA signatures in naturally micturated urine samples can provide valuable information for the evaluation of patients under investigation for BCa. Additional refinement and validation of promising multi-target signatures will support the development of accurate assays for the non-invasive detection and monitoring of BCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.